Product Description
Cenerimod, a novel, potent and selective S1P1 receptor modulator with unique S1P1 receptor signaling properties and absence of broncho- and vasoconstrictor effects ex vivo and in vivo. Cenerimod dose-dependently lowered circulating lymphocyte counts in rats and mice after oral administration and effectively attenuated disease parameters in a mouse experimental autoimmune encephalitis (EAE) model. Cenerimod has potential as novel therapy with improved safety profile for autoimmune diseases with high unmet medical need.
Mechanisms of Action: S1P1 Modulator
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Idorsia
Company Location:
Company CEO:
Additonal Commercial Interests: Viatris Pharmaceuticals
Clinical Description
Countries in Clinic: Argentina, Brazil, Bulgaria, Chile, Czech Republic, France, Georgia, Germany, Greece, Hungary, Japan, Korea, Mexico, Peru, Philippines, Poland, Portugal, Puerto Rico, Romania, Serbia, South Africa, Spain, Taiwan, United States, Unknown Location
Active Clinical Trial Count: 11
Highest Development Phases
Phase 3: Lupus Erythematosus, Systemic
Phase 1: Healthy Volunteers|Kidney Diseases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| ID-064A303 | P3 |
Unknown Status |
Lupus Erythematosus, Systemic |
2028-05-01 |
|
| OPUS OLE | P3 |
Enrolling by invitation |
Lupus Erythematosus, Systemic |
2027-11-01 |
|
| 2022-002814-17 | P3 |
Active, not recruiting |
Lupus Erythematosus, Systemic |
2026-12-16 |
|
| 2022-002815-47 | P3 |
Active, not recruiting |
Lupus Erythematosus, Systemic |
2026-12-14 |